Cite

HARVARD Citation

    Terzic, T. et al. (2018). Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Pediatric and developmental pathology. pp. 355-362. [Online]. 
  
Back to record